These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37980219)

  • 1. Past, Present, and Future Therapies for Alcohol-associated Hepatitis.
    Condon S; Jophlin LL
    Clin Ther; 2023 Dec; 45(12):1171-1176. PubMed ID: 37980219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcoholic hepatitis: Translational approaches to develop targeted therapies.
    Mandrekar P; Bataller R; Tsukamoto H; Gao B
    Hepatology; 2016 Oct; 64(4):1343-55. PubMed ID: 26940353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Strategies for the Treatment of Alcoholic Hepatitis.
    Singal AK; Shah VH
    Semin Liver Dis; 2016 Feb; 36(1):56-68. PubMed ID: 26870933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.
    Mitchell MC; Friedman LS; McClain CJ
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):5-12. PubMed ID: 27979049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Trial Design for Alcoholic Hepatitis.
    Szabo G
    Semin Liver Dis; 2017 Nov; 37(4):332-342. PubMed ID: 29272895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.
    Hassanein T; McClain CJ; Vatsalya V; Stein LL; Flamm SL; Martin P; Cave MC; Mitchell M; Barton B; Nagy L; Szabo G; McCullough A; Dasarathy S; Shah J; Blevins C; Scott D; Krebs W; Brown JE; Lin W
    Am J Gastroenterol; 2024 Jan; 119(1):107-115. PubMed ID: 37011138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic targets in alcoholic hepatitis.
    Arsene D; Farooq O; Bataller R
    Hepatol Int; 2016 Jul; 10(4):538-52. PubMed ID: 27072540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in Alcohol-Associated Hepatitis: Pathogenesis and Therapeutic Targets.
    Feng D; Hwang S; Guillot A; Wang Y; Guan Y; Chen C; Maccioni L; Gao B
    Cell Mol Gastroenterol Hepatol; 2024; 18(3):101352. PubMed ID: 38697358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial.
    Cho Y; Park YS; Kim HY; Kim W; Lee HJ; Kim DJ
    Trials; 2018 Dec; 19(1):696. PubMed ID: 30577864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcoholic hepatitis.
    Damgaard Sandahl T
    Dan Med J; 2014 Oct; 61(10):B4755. PubMed ID: 25283626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-22 in alcoholic hepatitis and beyond.
    Xiang X; Hwang S; Feng D; Shah VH; Gao B
    Hepatol Int; 2020 Sep; 14(5):667-676. PubMed ID: 32892258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial.
    Thursz M; Forrest E; Roderick P; Day C; Austin A; O'Grady J; Ryder S; Allison M; Gleeson D; McCune A; Patch D; Wright M; Masson S; Richardson P; Vale L; Mellor J; Stanton L; Bowers M; Ratcliffe I; Downs N; Kirkman S; Homer T; Ternent L
    Health Technol Assess; 2015 Dec; 19(102):1-104. PubMed ID: 26691209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcoholic hepatitis: Prognosis and treatment.
    Casanova J; Bataller R
    Gastroenterol Hepatol; 2014 Apr; 37(4):262-8. PubMed ID: 24656653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcoholic Hepatitis: Risk Factors, Pathogenesis, and Approach to Treatment.
    Yeluru A; Cuthbert JA; Casey L; Mitchell MC
    Alcohol Clin Exp Res; 2016 Feb; 40(2):246-55. PubMed ID: 26842243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review.
    Singal AK; Kodali S; Vucovich LA; Darley-Usmar V; Schiano TD
    Alcohol Clin Exp Res; 2016 Jul; 40(7):1390-402. PubMed ID: 27254289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy: New hope for alcoholic hepatitis?
    Gao B; Shah VH
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1(Suppl 1):S7-S11. PubMed ID: 26193867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and Management of Alcoholic Liver Disease.
    Farooq MO; Bataller R
    Dig Dis; 2016; 34(4):347-55. PubMed ID: 27170388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis.
    Vergis N; Patel V; Bogdanowicz K; Czyzewska-Khan J; Fiorentino F; Day E; Cross M; Foster N; Lord E; Goldin R; Forrest E; Thursz M
    Trials; 2021 Nov; 22(1):792. PubMed ID: 34763711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
    Teschke R
    Expert Opin Pharmacother; 2018 Jun; 19(8):779-793. PubMed ID: 29708448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.